translation agency

CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update
SPAIN: TB No Barrier to Anti-TNF Treatment
Nancy Walsh
November 19, 2012
MedPage Today External Web Site Policy, (11.16.2012)

The cytokine tumor necrosis factor (TNF) is important in protecting against TB infection; however TNF suppression is necessary for treating certain diseases. After the use of TNF inhibitors began, it was found that the suppression activated latent TB infection. The instructions for resuming TNF suppression in TB patients for treatment of other diseases—including arthritis—have not been very clear. The 2012 recommendations from the American College of Rheumatology announce that biologic therapy may be resumed after TB treatment. The guidelines from the British Society for Rheumatology hold that patients may continue on biologics if necessary during TB treatment, and the Spanish Society of Rheumatology states that there is no evidence of the optimal time for resumption. Researchers led by Maria Victoria Hernández, MD, of the Hospital Clinic of Barcelona, and colleagues conducted a retrospective study to determine the effects of timing in restarting biologic therapy for persons receiving TNF treatment. Data were taken from the Spanish Biologic Therapy Registry, which covered 6,479 patients. By November 2011, there were 52 cases of active TB. In all cases, biologic treatment was stopped, and in 27, anti-TNF therapy was resumed before TB treatment was completed. The 27 patients were classified as Group 1, and those who completed TB treatment before resuming biologic therapy were labeled Group 2. The median time for resumption of treatment was two months in Group 1 and 12 months in Group 2. There were 15 women in group 1; the mean age of the group was 57 years, and the mean disease duration was 19 years. Of the 27 patients, the underlying diagnosis was rheumatoid arthritis in 14, ankylosing spondylitis in 6, psoriatic arthritis in 3, juvenile idiopathic arthritis in 2, Behçet’s disease in 1, and undifferentiated spondyloarthropathy in 1. Of these patients, 20 were taking infliximab, 3 etanercept, and 4 adalimumab. The median time to resumption of TNF treatment was 2 months in group 1 and 12 months in group 2. In all but two patients, good control was achieved after resuming anti-TNF therapy, and patients remained on treatment. There was no evidence of relapse in the 27 patients during the four-year follow up. The researchers conclude that resumption of biologic therapy may not always need to be deferred; patients being treated with TNF inhibitors who develop TB may safely reinstitute TNF treatment before they complete TB treatment. Editor's note: [The study, "When Can Biological Therapy Be Resumed in Patients with Rheumatic Conditions Who Develop Tuberculosis Infection During Tumor Necrosis Factor Antagonist Therapy?" was presented at the 76th annual meeting of the American College of Rheumatology, November 9–14, 2012, Washington D.C., and was published in the American College of Rheumatology Abstract Supplement (2012; 64(10 supp.):(S701–S702)].